Clinical aspects of patients with sarcoglycanopathies under steroids therapy

被引:10
作者
Albuquerque, Marco A. V. [1 ]
Abath-Neto, Osorio [1 ]
Maximino, Jessica R. [1 ]
Chadi, Gerson [1 ]
Zanoteli, Edmar [1 ]
Reed, Umbertina C. [1 ]
机构
[1] Univ Sao Paulo, Fac Med, Dept Neurol, Sao Paulo, Brazil
关键词
steroids; limb-girdle muscular dystrophy; sarcoglycan proteins; myopathy; DUCHENNE MUSCULAR-DYSTROPHY; GLUCOCORTICOID TREATMENT; SKELETAL-MUSCLE; GENE-MUTATIONS; PREDNISOLONE; INSIGHTS; TRIAL;
D O I
10.1590/0004-282X20140126
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Patients with sarcoglycanopathies, which comprise four subtypes of autosomal recessive limb-girdle muscular dystrophies, usually present with progressive weakness leading to early loss of ambulation and premature death, and no effective treatment is currently available. Objective: To present clinical aspects and outcomes of six children with sarcoglycanopathies treated with steroids for at least one year. Method: Patient files were retrospectively analyzed for steroid use. Results: Stabilization of muscle strength was noted in one patient, a slight improvement in two, and a slight worsening in three. In addition, variable responses of forced vital capacity and cardiac function were observed. Conclusions: No overt clinical improvement was observed in patients with sarcoglycanopathies under steroid therapy. Prospective controlled studies including a larger number of patients are necessary to determine the effects of steroids for sarcoglycanopathies.
引用
收藏
页码:768 / 772
页数:5
相关论文
共 26 条
[1]  
Angelini C, 1998, MUSCLE NERVE, V21, P769, DOI 10.1002/(SICI)1097-4598(199806)21:6<769::AID-MUS9>3.0.CO
[2]  
2-5
[3]   The role of corticosteroids in muscular dystrophy: A critical appraisal [J].
Angelini, Corrado .
MUSCLE & NERVE, 2007, 36 (04) :424-435
[4]   Steroid treatment causes deterioration of myocardial function in the δ-sarcoglycan-deficient mouse model for dilated cardiomyopathy [J].
Bauer, R. ;
MacGowan, G. A. ;
Blain, A. ;
Bushby, K. ;
Straub, V. .
CARDIOVASCULAR RESEARCH, 2008, 79 (04) :652-661
[5]  
Bushby Kate, 2009, Pract Neurol, V9, P314, DOI 10.1136/jnnp.2009.193938
[6]  
Connolly AM, 1998, MUSCLE NERVE, V21, P1549
[7]   Molecular and genetic characterization of sarcospan:: insights into sarcoglycan-sarcospan interactions [J].
Crosbie, RH ;
Lim, LE ;
Moore, SA ;
Hirano, M ;
Hays, AP ;
Maybaum, SW ;
Collin, H ;
Dovico, SA ;
Stolle, CA ;
Fardeau, M ;
Tomé, FMS ;
Campbell, KP .
HUMAN MOLECULAR GENETICS, 2000, 9 (13) :2019-2027
[8]   Motor function measure scale, steroid therapy and patients with Duchenne muscular dystrophy [J].
da Silva, Elaine C. ;
Machado, Darlene L. ;
Resende, Maria B. D. ;
Silva, Renata F. ;
Zanoteli, Edmar ;
Reed, Umbertina C. .
ARQUIVOS DE NEURO-PSIQUIATRIA, 2012, 70 (03) :191-195
[9]   Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I [J].
Darin, N. ;
Kroksmark, A. -K. ;
Ahlander, A. -C. ;
Moslemi, A. -R. ;
Oldfors, A. ;
Tulinius, M. .
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2007, 11 (06) :353-357
[10]   Prednisolone-induced changes in dystrophic skeletal muscle [J].
Fisher, I ;
Abraham, D ;
Bouri, K ;
Hoffman, EP ;
Muntoni, F ;
Morgan, J .
FASEB JOURNAL, 2005, 19 (02) :834-+